Cantor Fitzgerald lowered shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) from a buy rating to a hold rating in a research report sent to investors on Wednesday. They currently have $42.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $19.00.
Several other research analysts have also issued reports on TBRA. Zacks Investment Research upgraded Tobira Therapeutics from a hold rating to a buy rating and set a $13.00 price target on the stock in a report on Wednesday, July 13th. HC Wainwright reiterated a buy rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Finally, Cowen and Company reiterated a buy rating and issued a $11.00 price target on shares of Tobira Therapeutics in a report on Wednesday, August 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $68.63.
Tobira Therapeutics (NASDAQ:TBRA) opened at 38.99 on Wednesday. The stock’s 50 day moving average price is $9.62 and its 200 day moving average price is $9.17. The company’s market capitalization is $733.83 million. Tobira Therapeutics has a 52 week low of $3.76 and a 52 week high of $41.39.
Tobira Therapeutics (NASDAQ:TBRA) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.08. The business earned $1.06 million during the quarter. Analysts anticipate that Tobira Therapeutics will post ($2.65) earnings per share for the current year.
In related news, major shareholder A/S Novo sold 59,067 shares of the stock in a transaction that occurred on Wednesday, July 13th. The stock was sold at an average price of $12.02, for a total transaction of $709,985.34. Following the completion of the sale, the insider now directly owns 1,914,541 shares of the company’s stock, valued at $23,012,782.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Pentwater Capital Management L purchased 1,624,200 shares of the firm’s stock in a transaction that occurred on Thursday, September 22nd. The shares were acquired at an average cost of $39.04 per share, with a total value of $63,408,768.00. The disclosure for this purchase can be found here. 6.20% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of TBRA. Franklin Resources Inc. acquired a new stake in shares of Tobira Therapeutics during the first quarter worth approximately $4,797,000. BB Biotech AG purchased a new stake in Tobira Therapeutics during the second quarter worth about $5,878,000. AXA purchased a new stake in Tobira Therapeutics during the second quarter worth about $3,472,000. BlackRock Fund Advisors increased its stake in Tobira Therapeutics by 256.8% in the second quarter. BlackRock Fund Advisors now owns 227,775 shares of the biopharmaceutical company’s stock worth $2,861,000 after buying an additional 163,943 shares in the last quarter. Finally, State Street Corp increased its stake in Tobira Therapeutics by 155.5% in the second quarter. State Street Corp now owns 109,527 shares of the biopharmaceutical company’s stock worth $1,377,000 after buying an additional 66,652 shares in the last quarter. 62.02% of the stock is owned by institutional investors.
About Tobira Therapeutics
Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.
Receive News & Ratings for Tobira Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tobira Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.